Evaluation of dithiol chelating agents as potential adjuvants for anti-IL-2 receptor lead or bismuth alpha radioimmunotherapy

Nuclear Medicine and Biology

Volumn 23, Issue 2, 1996, Pages 105-113

  Jones, Shaun B ^a   Tiffany, Linda Jones ^b   Garmestani, Kayhan ^c   Gansow, Otto A ^c   Kozak, Robert W ^b,d  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d BAYER CORPORATION   (United States)

Author keywords

Dithiol chelating; DMPS; Radiotoxicity

Indexed keywords

BISMUTH 206; BISMUTH 212; CHELATING AGENT; LEAD 212; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; MOUSE; PHARMACOKINETICS; RADIOIMMUNOTHERAPY; TUMOR CELL CULTURE;

EID: 0342960380     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/0969-8051(95)02006-3     Document Type: Article

References (27)

1. Aaseth J. (1983) Recent advances in the therapy of metal poisonings with chelating agents. Human Toxicol. 2, 257-272.
2. Aposhian H. V., Mershon M. M., Brinkley F. B., Hsu C.-A. and Hackley B. E. (1982) Anti-Lewisite activity and stability of meso-dimercaptosuccinic acid and 2,3-dimercapto-1-propanesulfonic acid. Life Sciences 31, 2149-2156.
3. 224Ra. Int. J. Radiat. Appl. Instrum. Part A 39, 283-286.
4. Broan C. J., Cox J. P. L., Craig A. S., Kataky R., Parker D., Harrison A., Randall A. M. and Ferguson G. (1991) Structure and solution stability of indium and gallium complexes of 1,4,7-triazacyclononanetriacetate and of yttrium complexes of 1,4,7,10-tetraazacyclododecanetetraacetate and related ligands: Kinetically stable complexes for use in imaging and radioimmunotherapy. X-ray molecular structure of the indium and gallium complexes of 1,4,7-triazacyclononane-1,4,7-triacetic acid. J. Chem. Soc. Perkin Trans. 2 1, 87-99.
5. Chisolm Jr. J. J. and Thomas D. J. (1985) Use of 2,3-dimercaptopropane-1-sulfonate in treatment of lead poisoning in children. J. Pharm. Exp. Ther. 235, 665-670.
6. Deshpande S. V., DeNardo S. J., Kukis D. L., Moi M. K., McCall M. J., DeNardo G. L. and Meares C. F. (1990) Yttrium-90-labeled monoclonal antibody for therapy: Labeling by a new macrocyclic bifunctional chelating agent. J. Nucl. Med. 31, 473-479.
7. Gabard B. (1978) Distribution and excretion of the mercury chelating agent sodium 2,3-dimercaptopropane-1-sulfonate in the rat. Arch. Toxicol. 39, 289-298.
8. Gabard B. (1980) Removal of internally deposited gold by 2,3-dimercaptopropane sodium sulphonate (Dimaval). Br. J. Pharmac. 68, 607-610.
9. Gansow O. A. (1991) Status of lead and bismuth for radioimmunoimaging and radioimmunotherapy. In New Trends in Radiopharmaceutical Synthesis, Quality Assurance, and Regulatory Control (Edited by Emran A. M.), pp. 227-246. Plenum Press, New York.
10. Gansow O. A., Brechbiel M. W., Pippin C. G., McMurray T. J., Lambrecht R., Colcher D., Schlom J., Roselli M., Strand M., Huneke R. B. and Ruegg C. L. (1991) Lead and bismuth complexes of functionalized DTPA ligands and of the polyazacycloalkane-N-acetic acid DOTA. Utility for radioimmunoimaging and radioimmunotherapy. Antib. Immunoconjug. Radiopharm. 4, 413-425.
11. 90Y-labeled monoclonal antibodies as a third line of treatment in ovarian cancer. A phase 1-2 trial: Problems encountered and possible solutions. Br. J. Cancer 62 (Suppl X), 48-51.
12. Kozak R. W., Atcher R. W., Gansow O. A., Friedman A. M., Hines J. J. and Waldmann T. A. (1986) Bismuth-212-labeled anti-Tac monoclonal antibody: α-Particle-emitting radionuclides as modalities for radioimmunotherapy. Proc. Natl. Acad. Sci. USA 83, 474-478.
13. Kozak R. W., FitzGerald D. P., Atcher R. W., Goldman C. K., Nelson D. L., Gansow O. A., Pastan I. and Waldmann T. A. (1990) Selective elimination in vitro of alloresponsive T cells to human transplantation antigens by toxin or radionuclide conjugated anti-IL-2 receptor (Tac) monoclonal antibody. J. Immunol. 144, 3417-3423.
14. Kozak R. W., Raubitschek A., Mirzadeh S., Brechbiel M. W., Junghaus R., Gansow O. A. and Waldmann T. A. (1989) Nature of the bifunctional chelating agent used for radioimmunotherapy with yttrium-90 monoclonal antibodies: Critical factors in determining in vivo survival and organ toxicity. Cancer Res. 49, 2639-2644.
15. Kozak R. W., Waldmann T. A., Atcher R. W. and Gansow O. A. (1985) Radionuclide-conjugated monoclonal antibodies: A synthesis of immunology, inorganic chemistry and nuclear science. Trends Biotechnol. 4, 259-264.
16. Kumar K., Magerstadt M. and Gansow O. A. (1989) Lead (II) and Bismuth (III) complexes of the polyazacycloalkane-N-acetic acids nota, dota and teta. J. Chem. Soc. Chem. Commun. 3, 145-146.
17. Macklis R. M., Kinsey B. M., Kassis A. I., Ferrara J. L. M., Atcher R. W., Hines J. J., Coleman C. N., Adelstein S. J. and Burakoff S. J. (1988) Radioimmunotherapy with alpha-particle-emitting immunoconjugates. Science 240, 1024-1026.
18. Maiorino R. M. and Aposhian H. V. (1989) Determination and metabolism of dithiol chelating agents. IV. Urinary excretion of meso-2,3-dimercaptosuccinic acid and mercaptosuccinic acid in rabbits given meso-2,3-dimercaptosuccinic acid. Biochem. Pharm. 38, 1147-1154.
19. Maiorino R. M., Dart R. C., Carter D. E. and Aposhian H. V. (1991) Determination and metabolism of dithiol chelating agents. XII. Metabolism and pharmacokinetics of sodium 2,3-dimercaptopropane-1-sulfonate in humans. J. Pharm. Exp. Ther. 259, 808-814.
20. 2-. Radiochim. Acta 60, 1-10.
21. Rosenberg Y. J., Malek T. R., Schaeffer D. E., Santoro T. J., Mark G. E., Steinberg A. D. and Mountz J. D. (1985) Unusual expression of IL-2 receptors and both the c-myb and c-raf oncogenes in T cell lines and clones from autoimmune MRL-lpr/lpr mice. J. Immunol. 134, 3120-3123.
22. Ruegg C. L., Anderson-Berg W. T., Brechbiel M. W., Mirzadeh S., Gansow O. A. and Strand M. (1990) Improved in vivo stability and tumor targeting of bismuth-labeled antibody. Cancer Res. 50, 4221-4226.
23. 206Bi in the normal rat. Radiat. Res. 63, 443-454.
24. Rygaard, J. (1973) Anatomy of the nude mouse. In Thymus and Self: Immunobiology of the Mouse Mutant Nude, pp. 60-76. Wiley, New York.
25. Slikkerveer A., Jong H. B., Helmich R. B. and de Wolff F. A. (1992) Development of a therapeutic procedure for bismuth intoxication with chelating agents. J. Lab. Clin. Med. 119, 529-537.
26. Szymanska J. A., Mogilnicka E. M. and Kaszper B. W. (1977) Binding of bismuth in the kidneys of the rat: the role of metallothionein-like proteins. Biochem. Pharmacol. 26, 257-258.
27. Szymanska J. A., Zychowicz M., Zelazowski A. J. and Piotrowski J. K. (1978) Effect of selenium on the organ distribution and binding of bismuth in rat tissues. Arch. Toxicol. 40, 131-141.